PRESS RELEASES

Date	Title
Mar 2, 2023	Ardelyx Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Feb 28, 2023	Ardelyx Publishes First Environmental, Social and Governance (ESG) Report
Feb 27, 2023	Ardelyx to Participate at the Cowen 43rd Annual Health Care Conference
Feb 23, 2023	Ardelyx to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 2, 2023
Feb 2, 2023	Ardelyx, Inc. Reports Employment Inducement Grants
Dec 29, 2022	FDA Grants Appeal for Ardelyx's XPHOZAH® (tenapanor)
Dec 23, 2022	Ardelyx, Inc. Reports Employment Inducement Grants
Dec 16, 2022	Ardelyx Provides Update on FDA Appeal for XPHOZAH® (tenapanor) for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis
Nov 22, 2022	Ardelyx to Present at the 34th Annual Piper Sandler Healthcare Conference
Nov 16, 2022	Ardelyx Announces FDA Advisory Committee Votes that the Benefits of XPHOZAH® (tenapanor) Outweigh its Risks for the Control of Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

FAQs

Email Alerts

Connect

Bay Area
34175 Ardenwood Boulevard
Fremont, CA 94555

Greater Boston
400 Fifth Avenue, Suite 210
Waltham, MA 02451

Phone: 617.675.ARDX (2739)

Inquiries:
General: info@ardelyx.com
Media: media@ardelyx.com
Investor: investor@ardelyx.com
Business Development: partnering@ardelyx.com